LAVA Therapeutics
LVTX
LVTX was delisted on the 20th of November, 2025.
20 hedge funds and large institutions have $44.3M invested in LAVA Therapeutics in 2021 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, 7 reducing their positions, and 1 closing their positions.
100% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 1
5% more funds holding
Funds holding: 19 → 20 (+1)
0.63% less ownership
Funds ownership: 31.88% → 31.24% (-0.63%)
9% less capital invested
Capital invested by funds: $48.6M → $44.3M (-$4.35M)
71% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$28.4K |
| 2 |
Axa
Paris,
France
|
+$18.1K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$11.5K |
| 4 |
CSS
Cubist Systematic Strategies
Stamford,
Connecticut
|
+$1.97K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$508K |
| 2 |
Millennium Management
New York
|
-$201K |
| 3 |
AWG
Alpha Wave Global
New York
|
-$125K |
| 4 |
BFM
Boothbay Fund Management
New York
|
-$109K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$59.5K |
LVTX Hedge Fund Activity: Q4 2021 in Review
20 of the 6,518 institutional investors tracked by Wall St. Rank reported a position in LAVA Therapeutics (LVTX) for Q4 2021, worth a combined $44.3M — down 8.9% from $48.6M a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new LVTX positions and 1 closed out — a net gain of 1 holder — while 2 added to existing stakes and 7 trimmed.
The largest buyer was Morgan Stanley, opening a new position worth an estimated $28.4K. The largest seller was Sphera Funds Management, cutting an estimated $508K.
- 20 institutional investors held LAVA Therapeutics (LVTX) as of Q4 2021, up from 19 in Q3 2021.
- Funds reported $44.3M of LAVA Therapeutics stock for Q4 2021, down 8.9% quarter-over-quarter.
- 2 funds opened new LAVA Therapeutics positions in Q4 2021 and 1 closed out, a net change of +1 holder.
- The largest LAVA Therapeutics buyer in Q4 2021 was Morgan Stanley, an estimated $28.4K added.
- The largest LAVA Therapeutics seller in Q4 2021 was Sphera Funds Management, an estimated $508K sold.
Based on aggregated 13F filings for Q4 2021.